/ Side by side
Tirzepatide vs CagriSema
A neutral, side-by-side look at Tirzepatide and CagriSema: what each one is, its class, half-life, storage, and the public sources behind it. Educational reference only, not medical advice, dosing, or a recommendation to use either compound.
Tirzepatide
Mounjaro · Zepbound
Full profile →CagriSema
Cagrilintide/Semaglutide
Full profile →| Attribute | Tirzepatide | CagriSema |
|---|---|---|
| Category | GLP-1 / Metabolic | GLP-1 / Metabolic |
| Half-life | ~5 days | About one week for both components, consistent with the weekly schedule used in trials |
| Common vial | 5, 10, 15, 20, 30, 60 mg | Varies |
| Reference | Verified | Verified |
What is Tirzepatide?
A dual GIP and GLP-1 receptor agonist with a fatty-diacid modification for albumin binding, studied for glycemic control in type 2 diabetes and for weight management. Its half-life supports once-weekly administration.
Sources
- FDA approvals: Mounjaro (2022), Zepbound (2023)
- Schneck et al., CPT Pharmacometrics Syst Pharmacol 2024
What is CagriSema?
A fixed-dose combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, studied in phase 3 trials for weight management and for glycemic control in type 2 diabetes. Both components are given on a weekly schedule. Not approved.
Sources
- NEJM 2025: coadministered cagrilintide and semaglutide in adults with overweight or obesity
- NEJM 2025: cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.